D’Or Institute for Research and Education

Running trials

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Takeda· Source

• Recruiting

  A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

  NCT06980480· Phase 3· Takeda· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

• Recruiting

  TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC

  NCT07074106· Phase 2· D'Or Institute for Research and Education· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Pfizer· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

• Enrolling by invitation

  Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project

  NCT06917794· D'Or Institute for Research and Education· Source

• Active, not recruiting

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· Phase 3· Genmab· Source

• Recruiting

  A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

  NCT06629779· Phase 3· Pfizer· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

  NCT06486441· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Agnostic Therapy in Rare Solid Tumors

  NCT06638931· Phase 2· Instituto do Cancer do Estado de São Paulo· Source

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

  NCT05668988· Phase 3· Dizal Pharmaceuticals· Source

• Active, not recruiting

  A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

  NCT04224493· Phase 3· Epizyme, Inc.· Source

• Active, not recruiting

  Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

  NCT03395197· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

  NCT03127631· McMaster University· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer7 recruiting
• Lung cancer4 recruiting
• Heart failure1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Withdrawn

  A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone

  NCT06104878· Takeda· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Novo Nordisk A/S· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

  NCT05592275· Phase 2· Eli Lilly and Company· Source

• Completed

  Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis

  NCT05180240· Phase 2· Cardiol Therapeutics Inc.· Source

• Completed

  Tolerance to Immunomodulatory Nutritional Therapy in Oncology Patients Undergoing Chemotherapy and Radiotherapy

  NCT07021378· D'Or Institute for Research and Education· Source

• Completed

  Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

  NCT03377491· Phase 3· NovoCure Ltd.· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Triple-negative breast cancer23 works · 1 trial
• Follicular lymphoma11 works · 1 trial